A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

June 20, 2023

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Relapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaRelapsed Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaRelapsed Follicular LymphomaRelapsed Marginal Zone LymphomaRelapse Diffuse Large B Cell LymphomaRelapsed Small Lymphocytic LymphomaRefractory Follicular LymphomaRefractory Marginal Zone LymphomaRefractory Small Lymphocytic LymphomaRichter TransformationRefractory Diffuse Large B-cell LymphomaTransformed Non-Hodgkin Lymphoma
Interventions
DRUG

BGB-21447

BGB-21447 will be administered orally

Trial Locations (39)

1023

RECRUITING

Auckland City Hospital, Auckland

11501

NOT_YET_RECRUITING

Nyu Langone Health Perlmutter Cancer Center At Nyu Langone Hospital Long Island, Mineola

20089

NOT_YET_RECRUITING

Istituto Clinico Humanitas, Rozzano

21000

NOT_YET_RECRUITING

Chu Dijon, Dijon

21287

NOT_YET_RECRUITING

Sidney Kimmel Comprehensive Cancer At Johns Hopkins, Baltimore

31100

NOT_YET_RECRUITING

Iuc Toulouse Oncopole, Toulouse

34090

NOT_YET_RECRUITING

Chu Montpellier Hopital Saint Eloi, Montpellier

37134

NOT_YET_RECRUITING

Centroricerche Cliniche Di Verona Srl, Verona

40138

NOT_YET_RECRUITING

Azienda Ospedaliera Universitaria Policlinico Santorsola Malpighi, Bologna

50263

RECRUITING

Mission Cancer and Blood, Waukee

75010

NOT_YET_RECRUITING

Hopital Saint Louis, Paris

80131

NOT_YET_RECRUITING

Istituto Nazionale Tumori Fondazione G Pascale, Napoli

100000

RECRUITING

Peking University Third Hospital, Beijing

110004

RECRUITING

Shengjing Hospital of China Medical University, Shenyang

130021

NOT_YET_RECRUITING

The First Hospital of Jilin University, Changchun

200000

NOT_YET_RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

200032

RECRUITING

Affiliated Zhongshan Hospital of Fudan University, Shanghai

210029

RECRUITING

Jiangsu Province Hospital, Nanjing

213000

NOT_YET_RECRUITING

The First Peoples Hospital of Changzhou, Changzhou

215006

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

250021

RECRUITING

Shandong Provincial Hospital, Jinan

276000

COMPLETED

Linyi Peoples Hospital, Linyi

300020

RECRUITING

Institute of Hematology and Hospital of Blood Disease, Tianjin

330006

RECRUITING

The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang

332000

RECRUITING

The First Affiliated Hospital of Nanchang University Branch Xianghu, Nanchang

350014

RECRUITING

Fujian Cancer Hospital, Fuzhou

430030

RECRUITING

Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan

443001

NOT_YET_RECRUITING

Yichang Central Peoples Hospitaljiangnan Branch, Yichang

450000

RECRUITING

Henan Cancer Hospital, Zhengzhou

610041

NOT_YET_RECRUITING

West China Hospital, Sichuan University, Chengdu

52242-1009

RECRUITING

University of Iowa Hospitals and Clinics, Iowa City

10016-2708

NOT_YET_RECRUITING

Laura and Isaac Perlmutter Cancer Center At Nyu Langone Health, New York

19107-4216

NOT_YET_RECRUITING

Thomas Jefferson University, Philadelphia

57105-2108

RECRUITING

Avera Cancer Institute, Sioux Falls

NSW 2148

RECRUITING

Blacktown Cancer and Haematology Centre, Blacktown

QLD 4217

RECRUITING

Pindara Private Hospital, Benowa

QLD 4101

NOT_YET_RECRUITING

Mater Cancer Care Centre, South Brisbane

VIC 3168

RECRUITING

Monash Health, Clayton

WA 6009

RECRUITING

Linear Clinical Research, Nedlands

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BeiGene

INDUSTRY